Evidence synthesis for decision making 3: Heterogeneity - Subgroups, meta-regression, bias, and bias-adjustment

Medical Decision Making

Volumn 33, Issue 5, 2013, Pages 618-640

  Dias, Sofia ^a   Sutton, Alex J ^b   Welton, Nicky J ^b   Ades, A E ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NONE

Author keywords

Bayesian meta analysis; comparative effectiveness; cost effectiveness analysis; systematic reviews

Indexed keywords

ARTICLE; BAYESIAN META-ANALYSIS; COMPARATIVE EFFECTIVENESS; COST-EFFECTIVENESS ANALYSIS; DECISION MAKING; EVIDENCE BASED MEDICINE; META ANALYSIS; REGRESSION ANALYSIS; SYSTEMATIC REVIEW (TOPIC); THEORETICAL MODEL;

BAYESIAN META-ANALYSIS; COMPARATIVE EFFECTIVENESS; COST-EFFECTIVENESS ANALYSIS; SYSTEMATIC REVIEWS;

DECISION MAKING; EVIDENCE-BASED MEDICINE; MODELS, THEORETICAL; REGRESSION ANALYSIS;

EID: 84879772042     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X13485157     Document Type: Article

References (56)

1. London, UK: NICE ; 2008:
2. Higgins JPT Green S, ed. Chichester, UK: The Cochrane Collaboration, Wiley ; 2008:
3. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995 ; 273 (5). 408-12
4. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008 ; 336: 601-5
5. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A. 2009 ; 172: 137-59
6. Ades AE, Lu G, Higgins JPT. The interpretation of random effects meta-analysis in decision models. Med Decis Making. 2005 ; 25 (6). 646-54
7. Welton NJ, White I, Lu G, Higgins JPT, Ades AE, Hilden J. Correction: interpretation of random effects meta-analysis in decision models. Med Decis Making. 2007 ; 27: 212-4
8. Spiegelhalter DJ, Abrams KR, Myles J New York: John Wiley ; 2004:
9. Thompson SG. Why sources of heterogeneity in meta-analyses should be investigated. BMJ. 1994 ; 309: 1351-5
10. Thompson SG 2 nd ed.London, UK: BMJ Books; 2001. p 157-75. Egger M Davey Smith G Altman D, ed. London, UK: BMJ Books ; 2001: 157-75.
11. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JPT. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012 ; 41: 818-27
12. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR Chichester, UK: John Wiley ; 2009:
13. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013 2013 ; 33 33 (5 5). 607-617
14. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013 ; 33 (5). 641-656
15. Sutton AJ Leicester, UK: University of Leicester ; 2002:
16. DiasSSuttonAJWeltonNJAdesAE. NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment. 2011. Available from: http://www.nicedsu.org.uk
17. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009 ; 28: 1861-81
18. Nixon R, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med. 2007 ; 26 (6). 1237-54
19. Draper NR, Smith H 3 rd ed.New York: John Wiley; 1998. New York: John Wiley ; 1998:
20. National Institute for Health and Clinical Excellence. Certolizumab pegol for the treatment of rheumatoid arthritis. 2010. Report No. TA186. Available from: http://guidance.nice.org.uk/TA186
21. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000 ; 10: 325-37
22. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B. 2002 ; 64 (4). 583-616
23. McIntosh MW. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med. 1996 ; 15: 1713-28
24. Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med. 1997 ; 16: 2741-58
25. Welton NJ, Ades AE, Carlin JB, Altman DG, Sterne JAC. Models for potentially biased evidence in meta-analysis using empirically based priors. J R Stat Soc Ser A. 2009 ; 172 (1). 119-36
26. Savovic J, Harris RJ, Wood L, et al. Development of a combined database for meta-epidemiological research. Res Synthesis Methods. 2010 ; 1: 212-25
27. Dias S, Welton NJ, Marinho VCC, Salanti G, Higgins JPT, Ades AE. Estimation and adjustment of bias in randomised evidence by using mixed treatment comparison meta-analysis. J R Stat Soc Ser A. 2010 ; 173 (3). 613-29
28. Salanti G, Dias S, Welton NJ, et al. Evaluating novel agent effects in multiple treatments meta-regression. Stat Med. 2010 ; 29: 2369-83
29. Dias S, Welton NJ, Ades AE. Study designs to detect sponsorship and other biases in systematic reviews. J Clin Epidemiol. 2010 ; 63: 587-8
30. Moreno SG, Sutton AJ, Ades AE, et al. Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Med Res Methodol. 2009 ; 9: 2
31. Moreno SG, Sutton AJ, Turner EH, et al. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ. 2009 ; 339: b2981
32. Turner RM, Spiegelhalter DJ, Smith GCS, Thompson SG. Bias modelling in evidence synthesis. J R Stat Soc Ser A. 2009 ; 172: 21-47
33. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 5: the baseline natural history model. Med Decis Making. 2013 ; 33 (5). 657-670
34. Madan J, Stevenson MD, Ades AE, Cooper KL, Whyte S, Akehurst R. Consistency between direct and indirect trial evidence: is direct evidence always more reliable?. Value Health. 2011 ; 14: 953-60
35. Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades AE New York: John Wiley ; 2012:
36. Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004 ; 23: 1663-82
37. Rothman KJ, Greenland S, Lash TL Modern Epidemiology. 3 rd ed.Philadelphia, PA: Lippincott, Williams & Wilkins; 2008. Philadelphia, PA: Lippincott, Williams & Wilkins ; 2008:
38. Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol. 2002 ; 55: 86-94
39. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med. 2002 ; 21: 371-87
40. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Stat Med. 1995 ; 14: 2057-79
41. Simmonds MC, Higgins JPT, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005 ; 2: 209-17
42. Higgins JPT, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta-analysis of continuous outcome data from individual patients. Stat Med. 2001 ; 20: 2219-41
43. Goldstein H, Yang M, Omar RZ, Turner RM, Thompson SG. Meta-analysis using multilevel models with an application to the study of class size effects. Appl Stat. 2000 ; 49: 399-412
44. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med. 2000 ; 19: 3417-32
45. Tudor Smith C, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med. 2005 ; 24: 1307-19
46. Whitehead A, Omar RZ, Higgins JPT, Savaluny E, Turner RM, Thompson SG. Meta-analysis of ordinal outcomes using individual patient data. Stat Med. 2001 ; 20: 2243-60
47. Tudor Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials. 2007 ; 8: 34
48. Achana FA, Cooper NJ, Dias S, et al. Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis. Stat Med. 2013 ; 32: 752-71
49. Saramago P, Sutton AJ, Cooper NJ, Manca A. Mixed treatment comparisons using aggregate and individual participant level data. Stat Med. 2012 ; 31: 3516-36
50. Donegan S, Williamson P, D'Alessandro U, Garner P, Tudor Smith C. Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: individual patient data may be beneficial if only for a subset of trials. Stat Med. 2013 ; 32: 914-30
51. Donegan S, Williamson P, D'Alessandro U, Tudor Smith C. Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates. Stat Med. 2012 ; 31: 3840-57
52. Simmonds MC, Higgins JPT. Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. Stat Med. 2007 ; 26: 2982-99
53. Riley RD, Abrams KR, Lambert PC, Sutton AJ, Thompson JR. An evaluation of bivariate random-effects meta-analysis for the joint synthesis of two correlated outcomes. Stat Med. 2007 ; 26: 78-97
54. Riley RD, Lambert PC, Staessen JA, Wang J, Gueyffier F, Boutitie F. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med. 2008 ; 27: 1870-93
55. Sutton AJ, Kendrick D, Coupland CAC. Meta-analysis of individual- and aggregate-level data. Stat Med. 2008 ; 27: 651-69
56. DiasSWeltonNJSuttonAJAdesAE. NICE DSU Technical Support Document 2: A generalised linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials. 2011. Available from: http://www.nicedsu.org.uk